COMP <GO>
HRMY vs MRK // OPERATING MARGIN
Harmony Biosciences Holdings Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: HRMY 8
— MRK 5
▲ OPERATING MARGIN LEADER: MRK
LAST: $38.76 (+0.44%) • MKT CAP: $2.25B
operating-margins
24.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
operating-margins
34.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HRMY VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HRMY | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.20% | 74.80% | +2.40 | HRMY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 63.00% | 20.70% | +42.30 | HRMY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.8x | 15.3x | -7.50 | HRMY | /valuation <GO> |
| Free Cash Flow Yield | 15.48% | 3.42% | +12.06 | HRMY | /fcf-yield <GO> |
| Operating Margin ACTIVE | 24.00% | 34.30% | -10.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | 18.30% | 28.10% | -9.80 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 21.50% | 1.30% | +20.20 | HRMY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.38 | 5.19 | +0.19 | HRMY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | HRMY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.0 | 51.7 | -1.70 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.9x | 18.4x | -6.50 | HRMY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.25B | $361.02B | -$358.77B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HRMY REV | MRK REV | HRMY GROSS % | MRK GROSS % | HRMY FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $868.5M | $65.01B | 77.2% | 74.8% | $347.9M | $12.36B |
| FY 2024 | $714.7M | $64.17B | 78.1% | 76.3% | $218.7M | $18.10B |
| FY 2023 | $582.0M | $60.12B | — | — | $219.4M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HRMY // BETA —
MRK // BETA 0.92